Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Multicenter, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

Phase I, Multicenter, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors PharmaMar

Most Recent Events

  • 29 Apr 2021 Results (N=244), Pharmacokinetic-pharmacodynamic analyses of pooled data from phase I studies A-0015 and A-005, and phase II studies B001, B-002, and B-0038 published in the Journal of Clinical Pharmacology
  • 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.
  • 13 Jun 2011 Actual end date changed from 24 Nov 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top